Cytokines, autoantibodies and viral antibodies in premorbid and postdiagnostic sera from patients with rheumatoid arthritis: Case-control study nested in a cohort of Norwegian blood donors

Annals of the Rheumatic Diseases

Volumn 67, Issue 6, 2008, Pages 860-866

  Jørgensen, Kristian T ^a   Wiik, A ^a   Pedersen, M ^a   Hedegaard, C J ^b   Vestergaard, B F ^a   Gislefoss, R E ^c   Kvien, T K ^d,e   Wohlfahrt, J ^a   Bendtzen, K ^b   Frisch, M ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b Rigshospitalet   (Denmark)

^c CANCER REGISTRY OF NORWAY   (Norway)

^d DIAKONHJEMMET HOSPITAL   (Norway)

^e UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; CYTOKINE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 4; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; VIRUS ANTIBODY;

ADULT; ARTICLE; BLOOD CHEMISTRY; BLOOD DONOR; BLOOD STORAGE; CASE CONTROL STUDY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; EPSTEIN BARR VIRUS; FEMALE; HUMAN; MALE; NORWAY; PARVOVIRUS; PATHOGENESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS;

ADULT; ANTIBODIES, VIRAL; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; BLOOD DONORS; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; PARVOVIRUS B19, HUMAN; PEPTIDES, CYCLIC; PROSPECTIVE STUDIES; RHEUMATOID FACTOR; TIME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 39749199890     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.073825     Document Type: Article

References (43)

1. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440.
2. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-61.
3. Huber LC, Distler O, Tamer I, Gay RE, Gay S, Pap T. Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology (Oxford) 2006;45:669-75.
4. McInnes IB, Gracie JA. Targeting cytokines beyond tumor necrosis factor-alpha and interleukin-1 in rheumatoid arthritis. Curr Pain Headache Rep 2005;9:405-11.
5. Miossec P. An update on the cytokine network in rheumatoid arthritis. Curr Opin Rheumatol 2004;16:218-22.
6. Ospelt C, Neidhart M, Gay RE, Gay S. Synovial activation in rheumatoid arthritis. Front Biosci 2004;9:2323-34.
7. Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2004;43:906-14.
8. van Venrooij WJ, van de Putte L. Is assaying autoantibodies useful for diagnosing early rheumatoid arthritis? Nat Clin Pract Rheumatol 2005;1:4-5.
9. Firestein GS. Immunologic mechanisms in the pathogenesis of rheumatoid arthritis. J Clin Rheumatol 2005;11(suppl 3):S39-44.
10. Prince HE. Biomarkers for diagnosing and monitoring autoimmune diseases. Biomarkers 2005;10(suppl 1):S44-9.
11. Rantapaa-Dahlqvist S. Diagnostic and prognostic significance of autoantibodies in early rheumatoid arthritis. Scand J Rheumatol 2005;34:83-96.
12. Klareskog L, Alfredsson L, Rantapaa-Dahlqvist S, Berglin E, Stolt P, Padyukov L. What precedes development of rheumatoid arthritis? Ann Rheum Dis 2004;63(suppl 2):ii28-31.
13. Raza K, Falciani F, Curnow SJ, Ross EJ, Lee CY, Akbar AN, et al. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res Ther 2005;7:R784-95.
14. Pedersen M, Jacobsen S, Klarlund M, Pedersen BV, Wiik A, Wohlfahrt J, et al. Environmental risk factors differ between rheumatoid arthritis with and without autoantibodies against cyclic citrullinated peptides. Arthritis Res Ther 2006;8:R133.
15. Aho K, Heliovaara M, Maatela J, Tuomi T, Palosuo T. Rheumatoid factors antedating clinical rheumatoid arthritis. J Rheumatol 1991;18:1282-4.
16. del PA, Knowler WC, Pettitt DJ, Bennett PH. The incidence of rheumatoid arthritis is predicted by rheumatoid factor titer in a longitudinal population study. Arthritis Rheum 1988;31:1239-44.
17. Halldorsdottir HD, Jonsson T, Thorsteinsson J, Valdimarsson H. A prospective study on the incidence of rheumatoid arthritis among people with persistent increase of rheumatoid factor. Ann Rheum Dis 2000;59:149-51.
18. Jonsson T, Thorsteinsson J, Valdimarsson H. Elevation of only one rheumatoid factor isotype is not associated with increased prevalence of rheumatoid arthritis - a population based study. Scand J Rheumatol 2000;29:190-1.
19. Nielen MM, van SD, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004;50:380-6.
20. Rantapää-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48:2741-9.
21. Thorsteinsson J, Bjornsson OJ, Kolbeinsson A, Allander E, Sigfusson N, Olafsson O. A population study of rheumatoid factor in Iceland. A 5-year follow-up of 50 women with rheumatoid factor (RF). Ann Clin Res 1975;7:183-94.
22. Aho K, von ER, Kurki P, Palosuo T, Heliovaara M. Antikeratin antibody and antiperinuclear factor as markers for subclinical rheumatoid disease process. J Rheumatol 1993;20:1278-81.
23. Kurki P, Aho K, Palosuo T, Heliovaara M. Immunopathology of rheumatoid arthritis. Antikeratin antibodies precede the clinical disease. Arthritis Rheum 1992;35:914-17.
24. Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2006;65:845-51.
25. Nielen MM, van SD, Reesink HW, Twisk JW, van de Stadt RJ, van der Horst-Bruinsma IE, et al. Simultaneous development of acute phase response and autoantibodies in preclinical rheumatoid arthritis. Ann Rheum Dis 2006;65:535-7.
26. Nijenhuis S, Zendman AJ, Vossenaar ER, Pruijn GJ, vanVenrooij WJ. Autoantibodies to citrullinated proteins in rheumatoid arthritis: clinical performance and biochemical aspects of an RA-specific marker. Clin Chim Acta 2004;350:17-34.
27. Balandraud N, Meynard JB, Auger I, Sovran H, Mugnier B, Reviron D, et al. Epstein-Barr virus load in the peripheral blood of patients with rheumatoid arthritis: accurate quantification using real-time polymerase chain reaction. Arthritis Rheum 2003;48:1223-8.
28. Balandraud N, Roudier J, Roudier C. Epstein-Barr virus and rheumatoid arthritis. Autoimmun Rev 2004;3:362-7.
29. Takeda T, Mizugaki Y, Matsubara L, Imai S, Koike T, Takada K. Lytic Epstein-Barr virus infection in the synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum 2000;43:1218-25.
30. Chen YS, Chou PH, Li SN, Tsai WC, Lin KH, Tsai KB, et al. Parvovirus b19 infection in patients with rheumatoid arthritis in Taiwan. J Rheumatol 2006;33:887-91.
31. Ishii KK, Takahashi Y, Kaku M, Sasaki T. Role of human parvovirus B19 in the pathogenesis of rheumatoid arthritis. Jpn J Infect Dis 1999;52:201-7.
32. Murai C, Munakata Y, Takahashi Y, Ishii T, Shibata S, Muryoi T, et al. Rheumatoid arthritis after human parvovirus B19 infection. Ann Rheum Dis 1999;58:130-2.
33. Jellum E, Andersen A, Lund-Larsen P, Theodorsen L, Orjasaeter H. Experiences of the Janus Serum Bank in Norway. Environ Health Perspect 1995;103(suppl 3):85-8.
34. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
35. Kvien TK, Uhlig T. The population based studies in rheumatoid arthritis. A method of longterm followup studies. J Rheumatol Suppl 2004;69:35-40.
36. Svenson M, Bagge HM, Bendtzen K. Distribution and characterization of autoantibodies to interleukin 1 alpha in normal human sera. Scand J Immunol 1990;32:695-701.
37. Vejtorp M, Hoier-Madsen M, Halberg P. Enzyme-linked immunosorbent assay for determination of IgM rheumatoid factor. Scand J Rheumatol 1979;8:65-70.
38. Vollset SE, Hirji KF, Afifi AA. Evaluation of exact and asymptotic interval estimators in logistic analysis of matched case-control studies. Biometrics 1991;47:1311-25.
39. Hirji KF, Tsiatis AA, Mehta CR. Median unbiased estimation for binary data. Am Stat 1989;43:7-11.
40. Koller MD. Targeted therapy in rheumatoid arthritis. Wien Med Wochenschr 2006;156:53-60.
41. Badolato R, Oppenheim JJ. Role of cytokines, acute-phase proteins, and chemokines in the progression of rheumatoid arthritis. Semin Arthritis Rheum 1996;26:526-38.
42. Arend WP. Physiology of cytokine pathways in rheumatoid arthritis. Arthritis Rheum 2001;45:101-6.
43. Nielen MM, van SD, Reesink HW, Twisk JW, van de Stadt RJ, van der Horst-Bruinsma IE, et al. Increased levels of C-reactive protein in serum from blood donors before the onset of rheumatoid arthritis. Arthritis Rheum 2004;50:2423-7.